KN-93 - CAS:139298-40-1 - CAS号查询_生物试剂_化学试剂_分析试剂

中文名称:	KN-93
英文名称:	KN-93
别名:	KN-93 (E)-N-(2-(((3-(4-Chlorophenyl)allyl)(methyl)amino)methyl)phenyl)-N-(2-hydroxyethyl)-4-methoxybenzenesulfonamide
CAS No:	139298-40-1	分子式:	C₂₆H₂₉ClN₂O₄S^.H₃Po₄	分子量:	599.03
CAS No:	139298-40-1
分子式:	C₂₆H₂₉ClN₂O₄S^.H₃Po₄
分子量:	599.03
MDL:	MFCD00236424

安全技术说明书(PDF) MSDS(PDF) 点击下载产品说明书(PDF) 点击下载技术规格说明书(PDF)

K10008 KN-93 ≥98% (HPLC) (psaitong)

相关产品

Cabamiquine succinate
CAS No：2444781-71-7
KN-93 phosphate
CAS No：1188890-41-6
Syntide2 TFA
CAS No：
CaMKII-IN-1
CAS No：1208123-85-6
A-484954
CAS No：142557-61-7
KN-93 hydrochloride
CAS No：1956426-56-4

包装规格：

5mg 25mg 100mg in glass bottle

溶解性：

溶于DMSO (25mg/ml)

产品描述：

基本信息

产品编号：	K10008
产品名称：	KN-93
CAS:	139298-40-1	储存条件	粉末	-20℃	四年

分子式：	139298-40-1		溶于液体	-80℃	两年
分子量	599.03			-20℃	1个月
化学名：	(E)-N-(2-(((3-(4-Chlorophenyl)allyl)(methyl)amino)methyl)phenyl)-N-(2-hydroxyethyl)-4-methoxybenzenesulfonamide
Solubility (25°C)：
体外:	DMSO	100 mg/mL (199.58mM)
	Ethanol	21 mg/mL (41.91mM)
	Water	Insoluble
体内(现配现用):	1.请依序添加每种溶剂：10% DMSO→40% PEG300→5% Tween-80 →45% saline Solubility: ≥ 0.83 mg/mL (1.66mM); Clear solution
	此⽅案可获得 ≥ 0.83 mg/mL (1.66mM，饱和度未知) 的澄清溶液。以 1mL ⼯作液为例，取 100μL 8.3 mg/mL 的澄清 DMSO 储备液加到 400μL PEG300 中，混合均匀；向上述体系中加⼊ 50μL Tween-80，混合均匀；然后继续加⼊ 450μL ⽣理盐⽔定容⾄ 1mL。
	2.请依序添加每种溶剂：10% DMSO→90% (20% SBE-β-CD in saline) Solubility: 0.83 mg/mL (1.66mM); Clear solution; Need ultrasonic and warming
	此⽅案可获得 0.83 mg/mL (1.66mM) 的澄清溶液。以 1mL ⼯作液为例，取 100μL 8.3 mg/mL 的澄清 DMSO 储备液加到 900μL 20% 的 SBE-β-CD ⽣理盐⽔⽔溶液中，混合均匀
	3.请依序添加每种溶剂：10% DMSO→90% corn oil Solubility: ≥ 0.83 mg/mL (1.66mM); Clear solution
	此⽅案可获得 ≥ 0.83 mg/mL (1.66mM，饱和度未知) 的澄清溶液，此⽅案不适⽤于实验周期在半个⽉以上的实验。以 1mL ⼯作液为例，取 100μL 8.3 mg/mL 的澄清 DMSO 储备液加到 900μL ⽟⽶油中，混合均匀。
＜1mg/ml表示微溶或不溶。
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

制备储备液

浓度溶液体积质量	1mg	5mg	10mg
1mM	1.9958mL	9.9792mL	19.9585mL
5mM	0.3992mL	1.9958mL	3.9917mL
10mM	0.1996mL	0.9979mL	1.9958mL
50mM	0.0399mL	0.1996mL	0.3992mL

生物活性

产品描述	一种具有磷酸化活性的CaMKII抑制剂，IC50：370nM。
靶点	Ki: 370nM (CaMK)
体外研究	After 2 days of KN-93 treatment, 95% of cells are arrested in G1. G1 arrest is reversible; 1 day after KN-93 release, a peak of cells had progressed into S and G2-M. KN-93 also blocks cell growth stimulated by basic fibroblast growth factor, plateletderived growth factor-BB, and epidermal growth factor in NIH 3T3 fibroblasts. KN-93 inhibits the H+ , K+ -ATPase activity but strongly dissipates the proton gradient formed in the gastric membrane vesicles and reduces the volume of luminal space. KN-93 (0.5μM) prevents increased LV developed pressure during action potential prolongation and early afterdepolarizations. Ca2+-independent CaM kinase activity is increased during early afterdepolarizations and this increase is prevented by KN-93. KN-93 (10μM )significantly inhibits the activation of CaMKII/NF-κB signaling induced by elevated glucose, and subsequently decreases the expression of VEGF, iNOS and ICAM-1 in Müller cells.
体内研究	KN-93 (1 mg/kg/day, i.p.) inhibits retinal vascular leakage induced by diabetes, and suppresses phosphorylation of CaMKII and NF-κB in diabetic retina.

推荐实验方法(仅供参考)

Cell Assay

Cell viability is assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) assay. Briefly, Müller cells are seeded at a density of 10×104 cells per well in 96-well plates and cultured until sub-confluence. Next, cells are treated with curcumin for 24 h before incubation with MTT (5 mg/mL) at 37°C in 5% CO2 atmosphere for 4 h. The culture medium is then removed, and the formazan formed in the reaction is dissolved in 150μL DMSO. The optical density of the solution is measured at 490nm using a multifunctional microplate reader. Cell viability in each well is presented as a percentage of the control (vehicle-treated group)

Animal Administration

Male Sprague-Dawley rats (8 weeks of age) weighing 180-200 g are used in this study. Rats are housed in ventilated microisolator cages with free access to water and food. The rats are randomLy assigned to receive either 60 mg/kg STZ intraperitoneally or citrate buffer alone. Rats are categorized as diabetic when blood glucose levels exceeded 16.7mM at 48 h after STZ treatment. Two weeks after the induction of diabetes, rats are divided randomLy into three subgroups: STZdiabetic rats (n=12), STZ-treated diabetic rats administered curcumin (n=12), or STZ-diabetic rats administered KN93 (n=12) for a 12-week period. Curcumin is suspended in saline containing 0.5% carboxymethylcellulose at a concentration of 20 mg/mL and administered via oral gavage at a total dose of 100 mg/kg/day. KN93 is administered by intraperitoneal injection at 1 mg/kg/day. Control STZ-treated diabetic rats and non-diabetic controls (n=12) are gavage administered saline containing 0.5% carboxymethylcellulose on a daily basis. Body weights and blood glucose levels are measured every 2 weeks.

保存条件：

-20℃

UN码：

HazardClass：

危害声明：

安全说明：

搜索质检报告(COA)

参考文献 & 客户发表文献